Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis

R Suri; R Grieve; C Normand; C Metcalfe; S Thompson; C Wallis; A Bush

Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis

R Suri, R Grieve, C Normand, C Metcalfe, S Thompson, C Wallis, A Bush

Bristol Medical School (PHS)

Research output: Contribution to journal › Article (Academic Journal) › peer-review

45 Citations (Scopus)

Abstract

Daily recombinant human deoxyribonuclease (rhDNase) is an established but expensive treatment in cystic fibrosis (CF). An alternative lower cost therapy is hypertonic saline (HS), which has been shown to improve lung function in short term studies. This study compares the costs and consequences of daily rhDNase with alternate day rhDNase and HS in children with CF.

Original language	English
Pages (from-to)	841-6
Number of pages	6
Journal	Thorax
Volume	57
Issue number	10
Publication status	Published - 2002

Handle.net

Persistent link

Cite this

@article{be06eb2843d942c1bb2d768b7a4be814,

title = "Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis",

abstract = "Daily recombinant human deoxyribonuclease (rhDNase) is an established but expensive treatment in cystic fibrosis (CF). An alternative lower cost therapy is hypertonic saline (HS), which has been shown to improve lung function in short term studies. This study compares the costs and consequences of daily rhDNase with alternate day rhDNase and HS in children with CF.",

author = "R Suri and R Grieve and C Normand and C Metcalfe and S Thompson and C Wallis and A Bush",

year = "2002",

language = "English",

volume = "57",

pages = "841--6",

journal = "Thorax",

issn = "0040-6376",

publisher = "BMJ Publishing Group",

number = "10",

}

TY - JOUR

T1 - Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis

AU - Suri, R

AU - Grieve, R

AU - Normand, C

AU - Metcalfe, C

AU - Thompson, S

AU - Wallis, C

AU - Bush, A

PY - 2002

Y1 - 2002

N2 - Daily recombinant human deoxyribonuclease (rhDNase) is an established but expensive treatment in cystic fibrosis (CF). An alternative lower cost therapy is hypertonic saline (HS), which has been shown to improve lung function in short term studies. This study compares the costs and consequences of daily rhDNase with alternate day rhDNase and HS in children with CF.

AB - Daily recombinant human deoxyribonuclease (rhDNase) is an established but expensive treatment in cystic fibrosis (CF). An alternative lower cost therapy is hypertonic saline (HS), which has been shown to improve lung function in short term studies. This study compares the costs and consequences of daily rhDNase with alternate day rhDNase and HS in children with CF.

M3 - Article (Academic Journal)

C2 - 12324668

SN - 0040-6376

VL - 57

SP - 841

EP - 846

JO - Thorax

JF - Thorax

IS - 10

ER -

Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis

Abstract

Handle.net

Fingerprint

Cite this